Skip to content
1st Counsel – Lifestyle
Author:
Dianthus Therapeutics, Inc.
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 1, 2026
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
September 29, 2026
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 2, 2026
Dianthus Therapeutics to Participate in Three Investor Conferences During September
September 1, 2026
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results
August 4, 2026
Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases
August 4, 2026
Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
August 3, 2026
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
July 2, 2026
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
June 29, 2026
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 2, 2026
1
2
Next Page
→